Asthma management with HFA-BDP (Qvar).
This report reviews the role of hydrofluoroalkane-beclomethasone dipropionate (HFA-BDP; Qvar, 3M, Laughborough) in the management of asthma, based on pharmacokinetic, efficacy and safety clinical trial data presented at a satellite symposium to the European Respiratory Society in 1998. Qvar provides equivalent efficacy and safety to chlorofluorocarbon-BDP at about half the dose.
London Chest Hospital.
R
R
Davies
C
C
Leach
B
B
Lipworth
R
R
Shaw
D018927:Anti-Asthmatic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000378:metabolism; D001507:Beclomethasone / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017402:Chlorofluorocarbons; D004305:Dose-Response Relationship, Drug; D006801:Humans; D012138:Respiratory Therapy
D018927:Anti-Asthmatic Agents; D000893:Anti-Inflammatory Agents; D017402:Chlorofluorocarbons; D001507:Beclomethasone